Breaking News, Collaborations & Alliances

Wyeth Continues Karo R&D Activities

Wyeth has agreed to take on all of Karo Bio’s future R&D activities under the companies’ drug discovery collaboration, beginning September 1, 2009.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth has agreed to take on all of Karo Bio’s future R&D activities under the companies’ drug discovery collaboration, beginning September 1, 2009. The collaboration aims to identify and select development candidates for treatment of inflammatory diseases, focusing on the liver X receptor (LXR) as target receptor. The two companies entered the collaboration in 2001. “We are pleased that this exciting LXR program continues within Wyeth. Since Wyeth will perform all future research and deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters